Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Tetraphase Pharmaceuticals Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Tetraphase Pharmaceuticals Inc. - Product Pipeline Review - 2014', provides an overview of the Tetraphase Pharmaceuticals Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Tetraphase Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Tetraphase Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Tetraphase Pharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Tetraphase Pharmaceuticals Inc.'s pipeline products Reasons to buy - Evaluate Tetraphase Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Tetraphase Pharmaceuticals Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Tetraphase Pharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Tetraphase Pharmaceuticals Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tetraphase Pharmaceuticals Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Tetraphase Pharmaceuticals Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Tetraphase Pharmaceuticals Inc. Snapshot 5 Tetraphase Pharmaceuticals Inc. Overview 5 Key Information 5 Key Facts 5 Tetraphase Pharmaceuticals Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Tetraphase Pharmaceuticals Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Tetraphase Pharmaceuticals Inc. - Pipeline Products Glance 11 Tetraphase Pharmaceuticals Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Tetraphase Pharmaceuticals Inc. - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Tetraphase Pharmaceuticals Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Tetraphase Pharmaceuticals Inc. - Unknown Stage Pipeline Products 15 Unknown Products/Combination Treatment Modalities 15 Tetraphase Pharmaceuticals Inc. - Drug Profiles 16 eravacycline 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecule for Bacterial Infections 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 TP-076 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 TP-138 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 TP-271 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 TP-433 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 TP-559 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 TP-600 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 TP-834 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Tetraphase Pharmaceuticals Inc. - Pipeline Analysis 28 Tetraphase Pharmaceuticals Inc. - Pipeline Products by Target 28 Tetraphase Pharmaceuticals Inc. - Pipeline Products by Route of Administration 29 Tetraphase Pharmaceuticals Inc. - Pipeline Products by Molecule Type 30 Tetraphase Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 31 Tetraphase Pharmaceuticals Inc. - Recent Pipeline Updates 32 Tetraphase Pharmaceuticals Inc. - Dormant Projects 36 Tetraphase Pharmaceuticals Inc. - Locations And Subsidiaries 37 Head Office 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Tetraphase Pharmaceuticals Inc., Key Information 5 Tetraphase Pharmaceuticals Inc., Key Facts 5 Tetraphase Pharmaceuticals Inc. - Pipeline by Indication, 2014 8 Tetraphase Pharmaceuticals Inc. - Pipeline by Stage of Development, 2014 9 Tetraphase Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2014 10 Tetraphase Pharmaceuticals Inc. - Phase III, 2014 11 Tetraphase Pharmaceuticals Inc. - Phase I, 2014 12 Tetraphase Pharmaceuticals Inc. - Preclinical, 2014 13 Tetraphase Pharmaceuticals Inc. - Discovery, 2014 14 Tetraphase Pharmaceuticals Inc. - Unknown, 2014 15 Tetraphase Pharmaceuticals Inc. - Pipeline by Target, 2014 28 Tetraphase Pharmaceuticals Inc. - Pipeline by Route of Administration, 2014 29 Tetraphase Pharmaceuticals Inc. - Pipeline by Molecule Type, 2014 30 Tetraphase Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2014 31 Tetraphase Pharmaceuticals Inc. - Recent Pipeline Updates, 2014 32 Tetraphase Pharmaceuticals Inc. - Dormant Developmental Projects,2014 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.